Our Team

RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.


News

  • 18 September 2018

    Positive PEACHTREE Data to be Highlighted at EURETINA 2018

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Ron Neumann , MD, Uveitis Specialist at  Maccabi Health Services ,  Tel Aviv, Israel  and co-Chair of the International Symposium of Ocular Pharmacology and Therapeutics, during a Uveitis Free Paper session at the upcoming  European Society of Retina Specialists (EURETINA) Congress  2018 in  Vienna, Austria.

  • 13 September 2018

    Data From Clearside Biomedicals Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitis to be Presented at the Retina Society 51st Annual Scientific Meeting

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by  Rahul N. Khurana , MD, an investigator for PEACHTREE, Partner at  Northern California Retina Vitreous Associates , and Clinical Associate Professor in Ophthalmology at  UCSF Medical Center , during a scientific session on Inflammation at the  Retina Society  51st Annual Scientific Meeting in  San Francisco , California.